



May 27, 2024

The Manager – Listing **BSE Limited** 1st Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: <u>Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulations, 2015</u>

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform that Mr. Ankush Nandra, Non-Executive Director has resigned from the office of Director of AstraZeneca Pharma India Limited with effect from close of working hours on May 27, 2024 due to change in his role and responsibilities that he will continue to pursue within AstraZeneca. While taking note of the same, the Board has placed on record its sincere thanks and appreciation for his contribution during his tenure in the Company.

As required under the Schedule III of the listing regulations, the resignation letter received from Mr. Ankush Nandra is attached herewith as Annexure -A.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited

Manasa. R Company Secretary

> CORPORATE & REGD. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000 FAX : +91 80 6774 8857 CIN : L24231KA1979PLC003563 WEB : www.astrazeneca.com/india FACTORY 12th Mile on Bellary Road Venkatala, Kattigenahalli Village Yelahanka Bangalore - 560 063 INDIA TEL : +91 80 6774 9000

FAX : +91 80 2846 2208 +91 80 6774 9628

Date: 27 May 2024

To: The Board of Directors AstraZeneca Pharma India Limited Bangalore India

Dear All,

Subject: Resignation from Board and Committees

I hereby submit my resignation as the Director of AstraZeneca Pharma India Limited ('the Company) and from the Nomination and Remuneration Committee of the Company, all with effect from the close of business hours (IST) on May 27, 2024. The reason is due to changes in my role and responsibilities at AstraZeneca.

I would like to express and record my sincere gratitude to my fellow Board members and the Company management for their support and guidance to me during my time on the Board. I will remember fondly my experience working with all of you and I wish you and the Company great success in the future.

Sincerely,

Wanda

Ankush Nandra